ABSTRACT
Diabetes mellitus is a serious medical and social problem, due to its high prevalence, a continuing trend toward an increase in the number of patients, a chronic course that determines the cumulative nature of the disease, and the high disability of patients. The most important problem of modern diabetology is the development of new, more effective methods of treating type 2 diabetes mellitus, designed to reduce the growth rate of the number of patients in the population, as well as significantly reduce the risk of micro- and macrovascular complications, polyneuropathy, increase the life expectancy of patients and minimize socio-economic losses. Modern problems of managing type 2 diabetes mellitus are aimed at achieving earlier and more stringent glycemic control, reducing postprandial peaks and hypoglycemic episodes, normalizing glycemic profile variability, and reducing insulin resistance.
Keywords: diabetes mellitus, sugar-lowering therapy, hypoglycemia, weight gain

---

REFERENCES

1. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2017 // Diabetes Care 2017; 40(Suppl. 1):S64-S74.
2. Garber A.J., Handelsman Y., Grunberger G., Einhorn D. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algoritm - 2020 Executive Summary // Endocrine Practice 2020, v.26, (No1), p.107-139.
3. Watanabe C.K. (1918) Studies in the metabolic changes induced by administration of guanidine bases // J. biol. Chem. 33, 253.
4. Summers S. Biguanides: [Elektron resurs] / -UK. Diabetes.co.uk, 15 th January, 2019. https://www.diabetes.co.uk/diabetes-medication/biguanides.html
5. Bailey C.J., Day C. Metformin: its botanical background // Pract Diab Int April 2004 Vol. 21 No. 3, p.115-117.
6. Li X., Li B., Ni Z., Zhou P. et al. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells // Molecular Cancer Therapeutics, 2017, v.16, Iss.9, p.1806-1818.
7. Fan Y.-P., Wu C.-T., Lin J.-L., Chao A. et al. Metformin Treatment Is Associated with a Decreased Risk of Nonproliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study // Journal of Diabetes Research, 2020, v.2020, Article ID 9161039, 12 p., https://doi.org/10.1155/2020/9161039
8. Hüseynova A. Метформин и недостатояность витамина В12 у больных сахарным диабетом типа 2 в Азербайджане // - Bakı: Azərbaycan Metobalizm Jurnalı, -2021. cild 18, N2, s.66-73.
9. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency // Diabetes Care. 2011;34:1431-1437.
10. Quianzon C.C.L., Cheikh I.E. History of current non-insulin medications for diabetes mellitus // Journal of Community Hospital Internal Medicine Perspectives 2012, 2: 19081, 4 p. - http://dx.doi.org/10.3402/jchimp.v2i3.19081
11. Douros A., Yin H., Yu O.H.Y., Filion K.B. et al. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events // Diabetes Care 2017; 40:1506-1513.
12. Hasslacher C for the Multinational Repaglinide Renal study Group.Safety and Efficacy of Repaglinide in Type 2 Diabetic Patients With and Without Impaired Renal Function // Diabetes Care 26:886-891, 2003.
13. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy // N Engl J Med. 2006; 355:2427-2443.
14. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial // Lancet. 2005; 366:1279-1289.
15. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT) // Diabetes Care. 2008; 31:845-851.
16. Abu-Hamdah R., Rabiee A., Meneilly G.S., Shannon R.P. et al. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides // J Clin Endocrinol Metab 2009; 94: 1843-1852.
17. Ahrén B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events // Best Pract Res Clin Endocrinol Metab. 2009; 23:487-498.
18. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes // N Engl J Med. 2015; 373:232-242.
19. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors // J Am Pharm Assoc (2003) 2009; 49(Suppl 1): S16-29.
20. Princeton. N. Victoza (liraglutide rDNA origin) injection prescribing information: [Elektron resurs] / -Denmark, Novo Nordisk, Inc; 2017 // https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf
21. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes // N Engl J Med. 2015; 373:2117-2128.
22. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition // Diabetes Care. 2015; 38:1687-1693.
23. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program // Diabetes Care. 2015;38: 1680-1686.